Brokerages forecast that Endologix, Inc. (NASDAQ:ELGX) will report ($0.22) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Endologix’s earnings, with estimates ranging from ($0.27) to ($0.17). Endologix also posted earnings per share of ($0.22) in the same quarter last year. The business is expected to report its next earnings report after the market closes on Wednesday, February 21st.
According to Zacks, analysts expect that Endologix will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.66) to ($0.56). For the next year, analysts expect that the company will report earnings of ($0.50) per share, with EPS estimates ranging from ($0.53) to ($0.46). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Endologix.
A number of brokerages have recently commented on ELGX. BidaskClub raised shares of Endologix from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Canaccord Genuity reissued a “hold” rating and issued a $5.00 target price on shares of Endologix in a research note on Wednesday, November 8th. Zacks Investment Research cut shares of Endologix from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Piper Jaffray Companies reissued an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th. Finally, ValuEngine cut shares of Endologix from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $5.41.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. ArrowMark Colorado Holdings LLC increased its stake in Endologix by 11.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 9,890,106 shares of the medical instruments supplier’s stock valued at $52,912,000 after acquiring an additional 1,043,986 shares during the period. Vanguard Group Inc. increased its stake in Endologix by 5.6% in the second quarter. Vanguard Group Inc. now owns 6,638,302 shares of the medical instruments supplier’s stock valued at $32,262,000 after acquiring an additional 353,233 shares during the period. BlackRock Inc. increased its stake in Endologix by 1.1% in the fourth quarter. BlackRock Inc. now owns 5,093,047 shares of the medical instruments supplier’s stock valued at $27,248,000 after acquiring an additional 56,745 shares during the period. Senzar Asset Management LLC increased its stake in Endologix by 143.6% in the fourth quarter. Senzar Asset Management LLC now owns 2,196,225 shares of the medical instruments supplier’s stock valued at $11,750,000 after acquiring an additional 1,294,684 shares during the period. Finally, State Street Corp increased its stake in Endologix by 11.5% in the second quarter. State Street Corp now owns 1,951,432 shares of the medical instruments supplier’s stock valued at $9,483,000 after acquiring an additional 201,700 shares during the period.
TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/19/zacks-analysts-expect-endologix-inc-elgx-to-announce-0-22-earnings-per-share.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.